AOD-9604 vs Survodutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
AOD-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. The idea was to keep the fat-burning end of growth hormone while leaving out the part that raises IGF-1 or messes with blood sugar. It was developed by Metabolic Pharmaceuticals in Australia and tested as an anti-obesity drug, but it is not approved by the FDA or any major regulator, and development stopped after it missed its weight-loss targets.
Also: BI 456906
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of mid-2026.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | AOD-9604 | Survodutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | In lab and animal studies, AOD-9604 appears to nudge fat cells toward breaking down stored fat (lipolysis) and away from making new fat (lipogenesis), echoing the lipolytic tail-end of the full growth hormone molecule. Unlike real growth hormone, it does this without meaningfully raising IGF-1, the downstream growth signal that drives growth hormone's anabolic and blood-sugar effects. The exact receptor it works through is not pinned down, and a clean, growth-hormone-receptor-independent pathway remains a working hypothesis rather than settled science. In short, the proposed selling point is fat-burning signaling without the classic growth hormone baggage, but the molecular details are still fuzzy. | The drug works on two fronts at once. The GLP-1 receptor arm dampens appetite, slows how fast the stomach empties, and improves blood sugar handling, the same lever that semaglutide pulls. The glucagon receptor arm is the twist: glucagon signaling raises energy expenditure and pushes the liver to burn fat rather than store it. The idea, still being proven out in trials, is that adding controlled glucagon activity to GLP-1 action burns more energy and clears liver fat faster than a GLP-1 drug alone, which is why survodutide is aimed squarely at fatty liver disease. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | Limited community data available See research protocols |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection weekly |
| Typical Duration | 12-24 weeks in studies | Long-term use expected |
| Best Time to Take | Morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal and cell data look encouraging, but the human story is where it falls apart. Across roughly six randomized, double-blind, placebo-controlled trials involving about 900 people, a safety review published in the Journal of Endocrinology and Metabolism (Moré et al.) found AOD-9604 was well tolerated, did not raise IGF-1, did not harm glucose metabolism, and triggered no detectable antibodies. The catch: it did not deliver clinically meaningful weight loss. The largest Phase IIb obesity trial failed to beat placebo on its main endpoint, and Metabolic Pharmaceuticals halted clinical development around 2007. So the honest summary is a peptide with a clean safety record in humans and essentially no proven efficacy for fat loss in humans. | This is one of the more advanced incretin dual agonists, and the human data are real, not hypothetical. In a Phase 2 MASH trial published in the New England Journal of Medicine in 2024 (Sanyal et al.), 293 biopsy-confirmed patients got weekly survodutide or placebo for 48 weeks, and MASH improved without worsening fibrosis in 47% of the 2.4 mg group and 62% of the 4.8 mg group, versus 14% on placebo. A separate Phase 2 obesity study showed weight loss up to roughly 18.7% at 46 weeks in completers. In April 2026, Boehringer Ingelheim and Zealand Pharma reported that the Phase 3 SYNCHRONIZE-1 obesity trial hit its mark with about 16.6% average weight loss. Large Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis) are ongoing. The catch worth knowing: nausea, vomiting, and other GI side effects are common, as with the whole incretin class, and final approval is not expected before 2027. |
Frequently Asked Questions: AOD-9604 vs Survodutide
What is the difference between AOD-9604 and Survodutide?
AOD-9604 is a weight loss peptide that aod-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. the idea was to keep the fat-burning end of growth hormone while leaving out the part that raises igf-1 or messes with blood sugar. it was developed by metabolic pharmaceuticals in australia and tested as an anti-obesity drug, but it is not approved by the fda or any major regulator, and development stopped after it missed its weight-loss targets. Survodutide is a weight loss peptide that survodutide is an injectable dual agonist that hits both the glp-1 and glucagon receptors, developed by boehringer ingelheim and zealand pharma. it is being tested for obesity and for fatty liver disease (mash), and it carries an fda breakthrough therapy designation for mash. it is still investigational and not approved for any use as of mid-2026. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Survodutide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Survodutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Survodutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Survodutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.